Search

Fate Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.48 -3.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.45

Max

2.63

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.2M

-31M

Verkäufe

-70K

1.3M

EPS

-0.26

Gewinnspanne

-2,402.848

Angestellte

161

EBITDA

14M

-28M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+101.54% upside

Dividenden

By Acuity

Nächstes Ergebnis

10. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

38M

291M

Vorheriger Eröffnungskurs

6.36

Vorheriger Schlusskurs

2.48

Nachrichtenstimmung

By Acuity

14%

86%

24 / 340 Ranking in Healthcare

Fate Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2026, 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4. Aug. 2026, 20:07 UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3. Aug. 2026, 23:01 UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29. Juli 2026, 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28. Juli 2026, 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27. Juli 2026, 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24. Juli 2026, 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23. Juli 2026, 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22. Juli 2026, 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20. Juli 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Peer-Vergleich

Kursveränderung

Fate Therapeutics Inc Prognose

Kursziel

By TipRanks

101.54% Vorteil

12-Monats-Prognose

Durchschnitt 5.24 USD  101.54%

Hoch 8 USD

Tief 2.2 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fate Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

5

Buy

4

Halten

0

Sell

Stimmung

By Acuity

24 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat